ICUI Key Statistics, Chart & Performance
The current stock price of ICUI is 146.98 USD. In the past month the price decreased by -3.24%. In the past year, price decreased by -4.84%.
ICUI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.99 | 16.42B | ||
| SOLV | SOLVENTUM CORP | 13.5 | 13.91B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.32 | 11.33B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.49 | 5.18B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.19 | 4.42B | ||
| HAE | HAEMONETICS CORP/MASS | 16.67 | 3.75B | ||
| XRAY | DENTSPLY SIRONA INC | 7.1 | 2.24B | ||
| UFPT | UFP TECHNOLOGIES INC | 27.29 | 1.82B | ||
| NEOG | NEOGEN CORP | 23.8 | 1.55B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.18B | ||
| EMBC | EMBECTA CORP | 4.07 | 706.80M | ||
| BVS | BIOVENTUS INC - A | 12.51 | 610.77M |
Related stock screener links
About ICUI
Company Profile
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 15,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
Company Info
ICU MEDICAL INC
951 Calle Amanecer
San Clemente CALIFORNIA 92763 US
CEO: Vivek Jain
Employees: 15000
Phone: 19493662183
ICU MEDICAL INC / ICUI FAQ
What does ICU MEDICAL INC do?
ICU Medical, Inc. engages in the provision of innovative medical products used in infusion therapy and critical care applications. The company is headquartered in San Clemente, California and currently employs 15,000 full-time employees. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, ClearGuard, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy products include Portex BLUselect PVC tracheostomy tubes.
What is the stock price of ICU MEDICAL INC today?
The current stock price of ICUI is 146.98 USD. The price decreased by -0.35% in the last trading session.
Does ICU MEDICAL INC pay dividends?
ICUI does not pay a dividend.
What is the ChartMill technical and fundamental rating of ICUI stock?
ICUI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of ICUI stock?
ICU MEDICAL INC (ICUI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the market cap for ICU MEDICAL INC?
ICU MEDICAL INC (ICUI) has a market capitalization of 3.63B USD. This makes ICUI a Mid Cap stock.
ICUI Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ICUI. When comparing the yearly performance of all stocks, ICUI turns out to be only a medium performer in the overall market: it outperformed 68.56% of all stocks.
ICUI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ICUI. ICUI has only an average score on both its financial health and profitability.
ICUI Financial Highlights
Over the last trailing twelve months ICUI reported a non-GAAP Earnings per Share(EPS) of 7.96. The EPS increased by 40.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.18% | ||
| ROE | -0.35% | ||
| Debt/Equity | 0.62 |
ICUI Forecast & Estimates
For the next year, analysts expect an EPS growth of 23.92% and a revenue growth -4.6% for ICUI